SEARCH

SEARCH BY CITATION

References

  • 1
    Dickstein K, Cohen-Solal A, Filippatos G, et al. For the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail 2008;10:933989.
  • 2
    Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:14501456.
  • 3
    CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomized trial. Lancet 1999;353:913.
  • 4
    MERIT-HF Study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:20012007.
  • 5
    Packer M, Coats AJ, Fowler MB, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:16511658.
  • 6
    Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: A population based study. Lancet 2001;358:439444.
  • 7
    Cleland JG, Cohen-Solal A, Aguilar JC, et al. IMPROVEMENT of Heart Failure Programme Committees and Investigators. Improvement programme in evaluation and management; Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): An international survey. Lancet 2002;360:16311639.
  • 8
    Komajda M, Lapuerta P, Hermans N, et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: The MAHLER survey. Eur Heart J 2005;26:16531659.
  • 9
    Lee DS, Tu JV, Juurlink DN, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 2005;294:12401247.
  • 10
    Uretsky BF, Sheahan RG. Primary prevention of sudden cardiac death in heart failure: Will the solution be shocking? J Am Coll Cardiol 1997;30:15891597.
  • 11
    Huirkuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:14731482.
  • 12
    Lane RE, Cowie MR, Chow AW. Prediction and prevention of sudden cardiac death in heart failure. Heart 2005;91:674680.
  • 13
    Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta-blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001;3:351357.
  • 14
    Foody JAM, Farrell MH, Krumholz HM. β-Blocker therapy in heart failure. JAMA 2002;287:883889.
  • 15
    Bouzamondo A, Hulot JS, Sanchez P, Lechat P. Beta-blocker benefit according to severity of heart failure. Eur J Heart Fail 2003;5:281289.
  • 16
    Cleland JG, Massie BM, Packer M. Sudden death in heart failure: Vascular or electrical?. Eur J Heart Fail 1999;1:4145.
  • 17
    Packer M. Pathophysiology of heart failure. Lancet 1992;340:8895.
  • 18
    Adamson PB, Vanoli E. Early autonomic and repolarization abnormalities contribute to lethal arrhythmias in chronic ischemic heart failure. Characteristics of a novel heart failure model in conscious dogs with post-myocardial infarction left ventricular dysfunction. J Am Coll Cardiol 2001;37:17411748.
  • 19
    Zipes DP, Rubart M. Neural modulation of cardiac arrhythmias and sudden cardiac death. Heart Rhythm 2006;3:108113.
  • 20
    Campbell DJ, Aggarwal A, Esler M, Kaye D. Betablockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet 2001;358:16091610.
  • 21
    Teisman AC, van Veldhuisen DJ, Boomsma F, et al. Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones. Int J Cardiol 2000;73:714.
  • 22
    Willenheimer R, Erdmann E, Follath F, et al. on behalf of the CIBIS-III investigators. Comparison of treatment initiation with bisoprolol versus enalapril in chronic heart failure patients: Rationale and Design of CIBIS-III. Eur J Heart Fail 2004;6:493500.
  • 23
    Willenheimer R, van Veldhuisen DJ, Silke B, et al. on behalf of the CIBIS III investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112:24262435.
  • 24
    Narang R, Cleland JGF, Erhardt L, et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 1996;17:13901403.
  • 25
    Solomon SD, Wang D, Finn P, et al. Effect of candesartan on cause-specific mortality in heart failure patients: The Candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program. Circulation 2004;110:21802183.
  • 26
    Cleland JG, Daubert JC, Erdmann E, et al. CARE-HF study Steering Committee and Investigators. The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): Rationale, design and end-points. Eur J Heart Fail 2001;3:481489.
  • 27
    Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:13091321.
  • 28
    Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997;349:971977.
  • 29
    Sliwa K, Norton GR, Kone N, et al. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coll Cardiol 2004;44:18251830.
  • 30
    Bristow MR, Gilbert EM, Abraham WT, et al. MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:28072816.
  • 31
    Dobre D, van Veldhuisen DJ, Mordenti G, et al. SENIORS Investigators. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: Data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. Am Heart J 2007;154:109115.
  • 32
    Simon T, Mary-Krause M, Funck-Brentano C, Lechat P, Jaillon P Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). Eur Heart J 2003;24:552559.
  • 33
    Dobre D, van Veldhuisen DJ, Goulder MA, Krum H, Willenheimer R. Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III trial. Cardiovasc Drugs Ther 2008;22:399405.